OncoMatch/Clinical Trials/NCT07218510
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Is NCT07218510 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Epcoritamab and Obinutuzumab for chronic lymphocytic leukemia.
Treatment: Epcoritamab · Obinutuzumab · Venetoclax — This phase II trial tests the effect of venetoclax and obinutuzumab followed by epcoritamab in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that have not previously received treatment. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Epcoritamab, a bispecific monoclonal antibody, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. The combination of venetoclax and obinutuzumab is a standard treatment for CLL/SLL and has been found to be safe and effective. Adding epcoritamab to standard treatment with venetoclax and obinutuzumab may lead to deeper and longer-lasting responses in patients with untreated CLL/SLL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 positivity
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: corticosteroid
Exception: steroids to treat autoimmune complications allowed
No prior treatment for CLL/SLL, except steroids and/or rituximab to treat autoimmune complications
Cannot have received: anti-CD20 therapy (rituximab)
Exception: rituximab to treat autoimmune complications allowed
No prior treatment for CLL/SLL, except steroids and/or rituximab to treat autoimmune complications
Lab requirements
Blood counts
Without bone marrow involvement: ANC ≥ 1,000/mm³; Platelets ≥ 50,000/mm³. With bone marrow involvement: ANC ≥ 500/mm³; Platelets ≥ 30,000/mm³. Growth factor not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement. Platelets independent of transfusion support, with no active bleeding.
Kidney function
Estimated creatinine clearance of ≥ 40 mL/min using the CKD-EPI 2009 formula
Liver function
Direct bilirubin ≤ 2 x upper limit of normal (ULN) (unless has Gilbert's disease or compensated hemolysis directly attributable to CLL); AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN
Direct bilirubin ≤ 2 x ULN (unless has Gilbert's disease or compensated hemolysis directly attributable to CLL); AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN; Estimated creatinine clearance of ≥ 40 mL/min using the CKD-EPI 2009 formula; ANC and platelet thresholds as above
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
- City of Hope at Irvine Lennar · Irvine, California
- City of Hope at Long Beach Elm · Long Beach, California
- University of Miami Miller School of Medicine-Sylvester Cancer Center · Miami, Florida
- City of Hope Atlanta Cancer Center · Newnan, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify